CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus Małgorzata Mikulska,

Slides:

Advertisements

Similar presentations

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Advertisements

Cytomegalovirus Status and the Outcome of T Cell–Replete Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Frans M. Verduyn Lunel,

Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation Stefania Coppoletta, Elisabetta Tedone,

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Admission of Hematopoietic Cell Transplantation Patients to the Intensive Care Unit at the Pontificia Universidad Católica de Chile Hospital Karen Escobar,

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui

How to Treat MDS without Stem Cell Transplantation

Vaccination of Children following Allogeneic Stem Cell Transplantation

Allogeneic Stem Cell Transplantation for Relapsed or Refractory Lymphoma after Conditioning with BEAM/Fludarabine/TBI Alix O’Meara, Jörg Halter, Dominik.

Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Reemergence of Gram-Negative Rods and Increasing Antibiotic Resistance

World Marrow Donor Association Crisis Response, Business Continuity, and Disaster Recovery Guidelines Julia Pingel, Cullen Case, Beth Amer, Raymond A.

Efficacy of a Viral Load-Based, Risk-Adapted, Preemptive Treatment Strategy for Prevention of Cytomegalovirus Disease after Hematopoietic Cell Transplantation

Major ABO Blood Group Mismatch Increases the Risk for Graft Failure after Unrelated Donor Hematopoietic Stem Cell Transplantation Mats Remberger, Emma.

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Sabina Kersting, Leo F. Verdonck

Cytomegalovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation: Risk Factors for Primary Infection and Cases of Recurrent and Late Infection.

Hepatitis C Virus Infection in Patients Undergoing Hematopoietic Cell Transplantation in the Era of Direct-Acting Antiviral Agents Andreas Kyvernitakis,

A Genetic Modifier of the Gut Microbiome Influences the Risk of Graft-versus-Host Disease and Bacteremia After Hematopoietic Stem Cell Transplantation

A Meta-Analysis of Unrelated Donor Umbilical Cord Blood Transplantation versus Unrelated Donor Bone Marrow Transplantation in Adult and Pediatric Patients

Betty T. Tran, Abigail Halperin, Jason W. Chien

Incidence Rate of Fluoroquinolone-Resistant Gram-Negative Rod Bacteremia among Allogeneic Hematopoietic Cell Transplantation Patients during an Era of.

Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Claudio G. Brunstein, Bruce R. Blazar, Jeffrey S

A Population-Based Cohort Study of Late Mortality in Adult Autologous Hematopoietic Stem Cell Transplant Recipients in Australia Lesley J. Ashton, Renate.

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Paul Szabolcs, Donna Niedzwiecki

Unmanipulated Haploidentical Bone Marrow Transplantation and Posttransplantation Cyclophosphamide for Hematologic Malignancies after Myeloablative Conditioning

B Cells and Transplantation: An Educational Resource

Kasiani C. Myers, Stella M. Davies

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Statistical Considerations in Studies of Late Effects in HCT

Incidence, Risk Factors, and Outcome of Cytomegalovirus Viremia and Gastroenteritis in Patients with Gastrointestinal Graft-versus-Host Disease Divaya.

Total Body Irradiation–Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation.

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation Stefania Coppoletta, Elisabetta Tedone,

Thymoglobulin Prevents Chronic Graft-versus-Host Disease, Chronic Lung Dysfunction, and Late Transplant-Related Mortality: Long-Term Follow-Up of a Randomized.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Costs of Hematopoietic Cell Transplantation: Comparison of Umbilical Cord Blood and Matched Related Donor Transplantation and the Impact of Posttransplant.

Disparity in Survival Outcome after Hematopoietic Stem Cell Transplantation for Hematologic Malignancies According to Area of Primary Residence Keshav.

Impact of Donor and Recipient Cytomegalovirus Serostatus on Outcomes of Antithymocyte Globulin–Conditioned Hematopoietic Cell Transplantation Amit Kalra,

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

HLA-Mismatched, Noninherited Maternal Antigen–Matched Unrelated Cord Blood Transplantations Have Superior Survival: How HLA Typing the Cord Blood Donor's.

Unmanipulated Haploidentical Transplants Compared with Other Alternative Donors and Matched Sibling Grafts Anna Maria Raiola, Alida Dominietto, Carmen.

What is quality in a transplant program?

Donor Serostatus Has an Impact on Cytomegalovirus-Specific Immunity, Cytomegaloviral Disease Incidence, and Survival in Seropositive Hematopoietic Cell.

Issues of Aging and Geriatric Medicine: Relevance to Cancer Treatment and Hematopoietic Reconstitution William B. Ershler, Andrew S. Artz, Evan T. Keller

Chronic Graft-Versus-Host Disease (cGVHD) following Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT): Higher Response Rate In Recipients.

Impact of HLA Disparity in Haploidentical Bone Marrow Transplantation Followed by High-Dose Cyclophosphamide Anna Maria Raiola, Antonio Risitano, Nicoletta.

Aplastic Anemia: Pathophysiology and Treatment

Blood and Marrow Transplant Handbook

Preengraftment Syndrome after Unrelated Cord Blood Transplant Is a Strong Predictor of Acute and Chronic Graft-versus-Host Disease Haydar Frangoul, Li.

Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation

Pre-Engraftment Bloodstream Infections after Allogeneic Hematopoietic Cell Transplantation: Impact of T Cell-Replete Transplantation from a Haploidentical.

Low Serum Levels of Total Rabbit-IgG Is Associated with Acute Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation:

Cytomegalovirus Infection after CD34+-Selected Hematopoietic Cell Transplantation Yao-Ting Huang, Dionysios Neofytos, Julia Foldi, Seong Jin Kim, Molly.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Sara C. Meyer, Alix O’Meara, Andreas S. Buser, André Tichelli, Jakob R

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Treatment versus Transplant for Challenging Hematologic Disorders

Wilms Tumor 1 Expression and Pre-emptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation

Hematopoietic Stem Cell Transplantation in Australia and New Zealand,

Effect of donor and recipient CMV serostatus on survival after HSCT in 2 large cohorts. Effect of donor and recipient CMV serostatus on survival after.

Outcomes among Patients with Recurrent High-Risk Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation Marco Mielcarek, Barry.

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

In Memoriam: E. Donnall Thomas

Daniel Couriel, Chitra Hosing, Rima Saliba, Elizabeth J

Optimal Donor Selection: Beyond HLA

Presentation transcript:

CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus Małgorzata Mikulska, Anna Maria Raiola, Paolo Bruzzi, Riccardo Varaldo, Silvana Annunziata, Teresa Lamparelli, Francesco Frassoni, Elisabetta Tedone, Barbara Galano, Andrea Bacigalupo, Claudio Viscoli Biology of Blood and Marrow Transplantation Volume 18, Issue 1, Pages 92-99 (January 2012) DOI: 10.1016/j.bbmt.2011.05.015 Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Cumulative incidence of CMV infection (180 days) in 2 types of HSCT donors: alternative versus cord blood. Biology of Blood and Marrow Transplantation 2012 18, 92-99DOI: (10.1016/j.bbmt.2011.05.015) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Percent of patients with CMV infection during the first 12 months after transplantation, divided according to donor type. Biology of Blood and Marrow Transplantation 2012 18, 92-99DOI: (10.1016/j.bbmt.2011.05.015) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Cumulative incidence of first CMV infection (180 days) in seropositive HSCT recipients divided according to donor serostatus and type of transplant. Biology of Blood and Marrow Transplantation 2012 18, 92-99DOI: (10.1016/j.bbmt.2011.05.015) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Median time (in days) between the first and last positive CMV antigenemia in CMV seropositive HSCT recipients divided according to donor serostatus and type of transplant. Biology of Blood and Marrow Transplantation 2012 18, 92-99DOI: (10.1016/j.bbmt.2011.05.015) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Cumulative incidence of late CMV infection in CMV seropositive HSCT recipients divided according to donor serostatus and type of transplant. Note: Incidence of late (>100 days after transplant) CMV infection, both in patients with and without previous early infection, was evaluated in 108 patients who survived more than 100 days after transplant. Biology of Blood and Marrow Transplantation 2012 18, 92-99DOI: (10.1016/j.bbmt.2011.05.015) Copyright © 2012 American Society for Blood and Marrow Transplantation Terms and Conditions